Ikonisys

Ikonisys Forward P/E

The Forward P/E Ratio of Ikonisys (ALIKO.PA) as of Oct 21, 2026 is -5.82. In the previous year, Forward P/E Ratio was -7.55 — a change of -22.92% (higher).

Forward P/E

-5.82

YoY

-22.92%

Last updated:

Forward P/E Ratio of Ikonisys is 2025 -5.82 . Forward P/E Ratio of Ikonisys was 2024 -7.55 . It decreases by -22.92% higher compared to the previous year.

The Ikonisys Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-13.03 EUR
Jan 1, 2020
-15.57 EUR
Jan 1, 2021
-42.84 EUR
Jan 1, 2022
-10.00 EUR
Jan 1, 2023
-10.79 EUR
Jan 1, 2024
-7.55 EUR
Jan 1, 2025
-5.82 EUR
The Ikonisys Forward P/E history
YEARForward P/EYoY
-5.82-22.92%
-7.55-30.01%
-10.79+7.97%
-10.00-76.67%
-42.84+175.22%
-15.57+19.50%
-13.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ikonisys Stock analysis

What does Ikonisys do? Ikonisys SA generates revenue through the sale of its cell diagnostic products, including oncoFISH bladder, oncoFISH her2, oncoFISH cervical, oncoFISH PTEN, oncoFISH ALK, and Explorer applications. These products are designed for cancer diagnosis, genetic disorder detection, and fertility testing, utilizing advanced molecular and immunological markers. The company's target customers are healthcare providers and clinical laboratories seeking accurate rare cell detection solutions. Ikonisys SA's offerings are tailored to specific medical applications such as bladder, breast, cervical, prostate, lung, and hematological cancer diagnostics, leveraging its proprietary Ikoniscope robotic components and digital microscope technology. The firm's product portfolio focuses on specialized diagnostic applications, with oncoFISH solutions targeting specific cancer types through molecular marker analysis. Explorer applications support hematological cancer diagnostics, while the underlying technology combines image acquisition, software engine, and digital microscopy for reliable cell detection. Ikonisys SA serves the healthcare sector by providing tools that enable precise diagnosis of genetic conditions and cancer types through its unique cellular analysis platform. Ikonisys SA's revenue streams are derived from the distribution of its diagnostic applications to clinical settings. The company's products are sold to healthcare institutions requiring advanced diagnostic capabilities for cancer, genetic disorders, and fertility issues. By offering targeted solutions like oncoFISH bladder for bladder cancer and oncoFISH her2 for breast cancer, Ikonisys SA addresses specific diagnostic needs within the medical field, utilizing its proprietary technology stack including Ikoniscope components and digital microscopy. Ikonisys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ikonisys stock

Forward P/E Ratio of Ikonisys is -5.82 in 2025.

Forward P/E Ratio of Ikonisys changed from -7.55 to -5.82, representing a -22.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Ikonisys since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Ikonisys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ikonisys

All Key Metrics — Ikonisys